Hyperforin Inhibits Akt1 Kinase Activity and Promotes Caspase-Mediated Apoptosis Involving Bad and Noxa Activation in Human Myeloid Tumor Cells by Merhi, Faten et al.
Hyperforin Inhibits Akt1 Kinase Activity and Promotes
Caspase-Mediated Apoptosis Involving Bad and Noxa
Activation in Human Myeloid Tumor Cells
Faten Merhi
1, Ruoping Tang
1,2, Marion Piedfer
1, Julie Mathieu
3, Isabelle Bombarda
4, Murhaf Zaher
1,
Jean-Pierre Kolb
1, Christian Billard
1, Brigitte Bauvois
1*
1INSERM U872, Universite ´ Pierre et Marie Curie, Universite ´ Paris Descartes, Centre de Recherche des Cordeliers, Paris, France, 2AP-HP, De ´partement d’He ´matologie,
Ho ˆpital St Antoine, Paris, France, 3INSERM U685, Ho ˆpital Saint-Louis, Paris, France, 4ISM2-AD2M, UMR CNRS 6263, Universite ´ Paul Ce ´zanne, Marseille, France
Abstract
Background: The natural phloroglucinol hyperforin HF displays anti-inflammatory and anti-tumoral properties of potential
pharmacological interest. Acute myeloid leukemia (AML) cells abnormally proliferate and escape apoptosis. Herein, the
effects and mechanisms of purified HF on AML cell dysfunction were investigated in AML cell lines defining distinct AML
subfamilies and primary AML cells cultured ex vivo.
Methodology and Results: HF inhibited in a time- and concentration-dependent manner the growth of AML cell lines
(U937, OCI-AML3, NB4, HL-60) by inducing apoptosis as evidenced by accumulation of sub-G1 population,
phosphatidylserine externalization and DNA fragmentation. HF also induced apoptosis in primary AML blasts, whereas
normal blood cells were not affected. The apoptotic process in U937 cells was accompanied by downregulation of anti-
apoptotic Bcl-2, upregulation of pro-apoptotic Noxa, mitochondrial membrane depolarization, activation of procaspases
and cleavage of the caspase substrate PARP-1. The general caspase inhibitor Z-VAD-fmk and the caspase-9- and -3-specific
inhibitors, but not caspase-8 inhibitor, significantly attenuated apoptosis. HF-mediated apoptosis was associated with
dephosphorylation of active Akt1 (at Ser
473) and Akt1 substrate Bad (at Ser
136) which activates Bad pro-apoptotic function.
HF supppressed the kinase activity of Akt1, and combined treatment with the allosteric Akt1 inhibitor Akt-I-VIII significantly
enhanced apoptosis of U937 cells.
Significance: Our data provide new evidence that HF’s pro-apoptotic effect in AML cells involved inhibition of Akt1
signaling, mitochondria and Bcl-2 members dysfunctions, and activation of procaspases -9/-3. Combined interruption of
mitochondrial and Akt1 pathways by HF may have implications for AML treatment.
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Introduction
Compiled literature demonstrates that many natural products
displaying anti-bacterial, anti-inflammatory or anti-tumoral effects
represent potential interest for the development of new drugs
especially designed for chemoprevention and chemotherapy of
various diseases [1–3]. Extracts of the plant St John’s wort,
Hypericum perforatum, have been used for centuries in traditional
medicine, notably for the treatment of depression [4–6]. Several
biologically active compounds have been isolated and character-
ized from these extracts, including naphthodianthrones, flavo-
noids, and phloroglucinols such as hyperforin (HF) (Figure 1) [6].
HF has been identified as the major molecule responsible for the
anti-depressant effects of this plant, and its neurobiological effects
include neurotransmitter re-uptake inhibition, the ability to
increase intracellular sodium and calcium levels, canonical
transient receptor potential activation and N-methyl-D-aspartic
acid receptor antagonism [4–6]. More recently, HF has been
shown to have the ability to disassemble amyloid-beta aggregates
in vitro, to decrease astrogliosis and microglia activation, as well as
to improve spatial memory in a rat model, thus suggesting a
potential role of HF in the treatment of Alzheimer’s disease [7].
HF displays several other biological properties of potential
pharmacological interest. They include antibacterial and antiox-
idant properties, and inhibitory effects on inflammatory mediators
[5,6]. HF acts as a dual inhibitor of 5-lipooxygenase and of
cyclooxygenase 1, hence its interest in the treatment of
inflammatory and allergic diseases connected to eicosanoids
[5,8]. HF inhibits the capacity of migration and invasion of
different cell types, and inhibits urokinase, elastase and matrix
metalloproteinases-2 and -9 involved in the degradation of the
extracellular matrix, an early step in the process of angiogenesis
[9]. The anti-angiogenic properties of HF were demonstrated in
vitro and in vivo [10]. In cytokine-activated endothelial cells, HF
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numerous genes involved in cell growth, survival, angiogenesis and
invasion [11]. As regards the immune system, HF inhibits the
proliferation of peripheral blood mononuclear cells without
displaying toxic effects whereas the incubation of endothelial cells
with HF suppresses the proliferation of alloreactive T cells [5]. In
the context of cancer, HF effectively inhibits the growth of a
number of mammalian cancer cell lines in vitro [4,5]. HF induces
apoptosis in the K562 (chronic myeloid leukemia) and U937 (acute
myeloid leukemia) cell lines through a caspase-dependent pathway
[12,13]. Our group previously reported that HF promotes in vitro a
mitochondrial caspase-dependent apoptosis of primary malignant
cells from patients with chronic lymphocytic leukemia [14] and
this was associated with the activation of the pro-apoptotic protein
Noxa [15].
Acute myeloid leukemia (AML) is a deadly disease characterized
by the clonal expansion and accumulation of hematopoietic stem
cells arrested at various stages of development. The latter are used
to define distinct AML subfamilies [16]. Leukemia cells are unable
to undergo (i) growth arrest, (ii) terminal differentiation, (iii)
apoptosis in response to appropriate environmental stimuli, and
disseminate from the bone marrow into peripheral tissues [16].
The conventional chemotherapeutic approach for AML patients is
based on treatment combinating an anthracycline with cytarabine
[16]. However AML therapy remains a challenge for clinicians
because a large subset of patients are still refractory to primary
therapies or relapse later. New drugs are currently in clinical
development including inhibitors of tyrosine kinases, farnesyl-
transferase inhibitors, histone deacetylase inhibitors or deoxyade-
nosine analogues [16–18]. Other approaches are based on the
identification of natural compounds capable of inducing apoptosis
which is deficient in AML.
In this study, we sought to determine whether purified HF could
show evidence of single drug activity in AML disease through
inhibition of growth and survival processes. In addition, the
underlying mechanisms and intracellular signaling pathways
affected by HF in AML cells were investigated. Understanding
HF’s pro-apoptotic activity in AML may provide new therapeutic
approaches for halting AML-associated survival.
Results
HF induces growth arrest and apoptosis in AML cell lines
We first examined the effects of HF on the growth and viability
of U937 cells (monoblastic phenotype M5). Cells were cultured for
72 h in the absence or presence of increasing concentrations (0.2–
3 mg/ml) of HF. Cell growth was markedly reduced in HF-treated
samples, when compared with vehicle or no treatment (Figure 2A).
The IC50 value (half-maximal inhibitory concentration) was
around 1 mg/ml (1.8 mM). Kinetic studies revealed a time-
dependent inhibitory effect of HF on U937 cell growth
(Figure 2B). Cell growth inhibition was accompanied by reduction
in DNA content to sub-G1 levels (Figure 2C) and internucleosomal
DNA fragmentation (Figure 2D) characteristic of apoptosis. The
positive control flavopiridol induced similar DNA fragmentation
[19] (Figure 2D). Apoptosis was further confirmed by phospha-
tidylserine exposure at the cell surface, with consequential
annexin-V-FITC binding whereas necrotic cells were detected
by PI staining. Indeed, annexin-V binding was higher in HF-
treated cells than in untreated cells (Figure 3A). The HF pro-
apoptotic effects was dose- (Figure 3B) and time-dependent
(Figure 3C). The other AML cell lines HL-60 (myeloblastic
phenotype M2), NB4 (promyelocytic phenotype M3) and OCI-
AML3 (myelomonocytic phenotype M4) were also found sensitive
to the inhibitory effects of HF (Figure 3D).
HF induces apoptosis in primary AML cells
We investigated the effect of HF on peripheral blood
mononuclear cells PBMCs obtained from 22 AML patients. The
leukemic cells were exposed to HF (1, 1.4 and 2 mg/ml) and
annexin-V binding was measured by flow cytometry after 24, 48
and 72 h. Cultured AML cells exhibited variable baseline levels of
spontaneous apoptosis independently of the FAB subtype (Figure 4
for 72 h culture). As exemplified in Figure 4, the optimal effects of
HF in inducing apoptosis of responding AML cells in culture were
achieved by 72 h with 2 mg/ml HF. Exposure to HF increased
apoptosis ($20% of response) in 14 of the 22 samples from FAB-
M0, M1, M2, M3 and M5 patients (Figure 4). The two samples
from M4 patients did not respond to HF treatment. As previously
reported [14,15], HF did not markedly affect the viability of
normal PBMCs (Figure 4).
HF-induced apoptosis involves a caspase-dependent
mechanism
Caspases -3, -8 and -9 are important mediators of apoptosis;
caspases -8 and -9 are the initiator caspases and caspase-3 is the
‘‘executioner enzyme’’ [20]. HF did not appear to activate
caspases directly (B Bauvois, unpublished results). We studied the
ability of U937 cell lysates to cleave chromogenic substrates of
caspase-3, caspase-8 and caspase-9. Untreated U937 cells display
similarly low baseline levels of all three caspase activities. The
broad-spectrum caspase inhibitor Z-VAD-fmk inhibited caspase
activities (data not shown). No changes were observed in the levels
of caspase activities up to 14 h in HF-treated cells relative to the
untreated cells (Figure 5A). By 24 h, cell treatment with HF
resulted in a marked increase in all three caspase activities relative
to untreated cells (Figure 5A). Accordingly, Western blot analyses
showed that exposure of U937 cells to increasing concentrations of
Figure 1. Chemical structure of hyperforin HF. 5-hydroxy-6R-
methyl-1R,3,7S-tris(3-methyl-2-butenyl)-5S-(2-methyl-1-oxopropyl)-6R-
(4-methyl-3-pentenyl)-bicyclo[3.3.1]non-3-ene-2,9 dione; C35H52O4;
536 g/mol. HF was purified according to the method described [75]
(purity$98%) and yielded less than 1% hypericin. HF was stored frozen
in EtOH under conditions preventing its sensitivity to light, oxygen and
aqueous solvents.
doi:10.1371/journal.pone.0025963.g001
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ADP-ribose polymerase-1 (PARP-1) (Figure 5B). Similar patterns
of PARP-1 degradation were observed with NB4 and OCI-AML3
cells (Figure 5B).
To determine whether the activated caspases are involved in the
apoptotic action of HF, we examined the effects of the broad-
spectrum caspase inhibitor Z-VAD-fmk and selective inhibitors of
caspase-3 (Z-DEVD-fmk), caspase-8 (Z-IETD-fmk) and caspase-9
(Ac-LEHD-CHO) on cell apoptosis as determined by annexin-V-
FITC binding. HF-mediated apoptosis was blocked markedly by
50 mM Z-VAD-fmk, Ac-LEHD-CHO and Z-DEVD-fmk
(Figure 5C), but not by Z-IETD-fmk (Figure 5C). In etoposide-
treated U937 cells used as a positive control [21], this dose of Z-
IETD-fmk was however efficient in blocking apoptosis (data not
shown). Together these results show that HF induces apoptosis at
least through the activation of caspases-9 and -3 in the intrinsic
pathway.
HF induces mitochondrial membrane depolarization, Bcl-
2 downregulation and Noxa upregulation
To confirm the intrinsic pathway’s involvement in HF-
induced apoptosis, we investigated the role of the mitochon-
dria. In a fluorescence-based assay, the exposure of U937 cells
to HF (1.4 mg/ml) and flavopiridol (positive control, 100 nM)
induced a marked decrease in the mitochondrial membrane
potential (Figure 6A&B). Mitochondrial membrane depolar-
ization can result from the action of pro-apoptotic and/or anti-
apoptotic members of the Bcl-2 family [20]. We therefore
measured expression levels of Bcl - 2a n dM c l - 1a n t i - a p o p t o t i c
proteins and Bax and Noxa pro-apoptotic proteins before and
after HF treatment. Untreated U937 cells expressed high levels
of Bcl-2, Mcl-1, Bax and Noxa (Figure 6C). At 24 h culture,
HF downregulated Bcl-2 in a dose-dependent manner while
the levels of Mcl-1 appeared to be diminished for 2 mg/ml HF
(Figure 6C). Moreover, HF upregulated Noxa in a dose-
dependent manner whereas no significant changes were
observed in the levels of Bax at 1 and 1.4 mg/ml HF when
normalized to actin levels (Figure 6C). Bax levels were slightly
diminished for 2 mg/ml HF (Figure 6C). Consistently with
previous studies in U937 cells [22,23], Bcl-2, Bax and Mcl-1
levels were lower in flavopiridol-treated cells than in untreated
cells (Figure 6C). Bid is a known substrate of caspases, and the
production of truncated Bid (tBid) can activate the intrinsic
pathway of apoptosis [24]. Untreated cells expressed high
levels of Bid, and HF treatment led to a concentration-
dependent loss of intact Bid (Figure 6C). We were however
unable to detect the formation of tBid fragments (14–15 kDa)
(data not shown).
Figure 2. Effects of HF on U937 cell growth. U937 cells (10
5/ml) were treated with HF (A) at the indicated concentrations for 72 h or (B) or with
0.5 and 1.4 mg/ml HF for the indicated times. Control EtOH (vehicle). Cell growth was measured by direct cell counting (in duplicates). Data are the
mean 6 SD of results from at least 6 independent experiments, each performed in duplicates. (C) U937 cells were incubated with 1.4 mg/ml HF for
72 h. Cells were stained with PI and DNA contents analyzed by flow cytometry. (D) DNA fragmentation in U937 cells treated for 72 h with 1.4 mg/ml
HF, EtOH (vehicle) or 100 nM flavopiridol (F).
doi:10.1371/journal.pone.0025963.g002
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annexin-V-FITC/propidium iodide staining and flow cytometry. Results are expressed as log PI fluorescence intensity (y-axis) vs log annexin-V-FITC
fluorescence intensity (x-axis). L1, necrotic cells; L2, apoptotic + secondary necrotic cells; L3, healthy cells; L4, apoptotic cells. (B) Percent of apoptotic
cells (L2+L4 gates) treated at the indicated concentrations for 72 h. Data are the mean 6 SD of results from at least 4 independent experiments. (C)
Percent of apoptotic cells (L2+L4 gates) treated with 1 or 1.4 mg/ml HF for the indicated times. Data are the mean 6 SD of results from at least 4
independent experiments. (D) AML cell lines were treated 1.4 mg/ml HF for 72 h. Cell growth was quantified as % of untreated cells. Percent of
apoptotic cells was determined as in (B). Data are the mean 6 SD of results from at least 4 independent experiments (n=4 for HL-60, OCI and NB4,
n=8 for U937). Basal apoptosis was #10% for HL-60 and U937, #20% for OCI and NB4).
doi:10.1371/journal.pone.0025963.g003
Figure 4. HF treatment induces apoptosis in primary AML cells. AML cells are characterized by the French American British (FAB) M0/
undifferentiated, M1/myeloblastic, M2/myeloblastic with maturation, M3/promyelocytic, M4/myelomonocytic and M5/monoblastic phenotypes.
PBMCs (10
6/ml) from normal donors (n=4) and AML patients were cultured with or without HF 2 mg/ml for 72 h, and then stained with annexin-V-
FITC/PI and analyzed by flow cytometry to assess the percentage of apoptotic cells (L2+L4 gates) in untreated (basal apoptosis) and HF-treated
cultures.
doi:10.1371/journal.pone.0025963.g004
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of Akt1 and Bad
Bad, a member of Bcl-2 family is a direct downstream target of
Akt1 [25]. Dephosphorylation of Bad on Ser
136 induces apoptosis
in primary AML cells [26]. U937 cells were negative for Ser
112-
phospho(p)-Bad (data not shown) and positive for Ser
136-p-Bad
(Figure 7A). A marked decrease in the level of Ser
136-p-Bad was
seen in response to HF while there was no change in the levels of
total Bad (Figure 7A). Since active Ser
473-p-Akt1 can negatively
regulate apoptosis through phosphorylation of Bad on Ser
136 [27],
we measured the level of Ser
473-p-Akt1 in U937 cells before and
after HF treatment. Accordingly, the amount of Ser
473-p-Akt1 was
decreased in HF-treated U937 cells at 24 h while the amount of
total Akt1 protein was not affected (Figure 7A). Consistently with
previous studies in myeloid cells [28,29], the levels of Ser
473-p-
Akt1 were also decreased in flavopiridol-treated cells (Figure 7A).
We thus examined whether HF might directly inhibit the kinase
activity of Akt1 in vitro using an ELISA that utilizes a specific
synthetic peptide as a substrate for active recombinant Akt1 and a
polyclonal antibody that recognizes the phosphorylated form of
the substrate. Flavopiridol and the highly specific allosteric Akt1/2
inhibitor Akt-I-VIII were also assayed for their ability to inhibit
Akt1 activity. As expected, Akt-I-VIII suppressed Akt1 kinase
activity with a IC50 value of 1.3 mM (Figure 7B). Surprisingly, HF
showed also a marked inhibitory activity for Akt1 with a IC50
value of 2.5 mM (1.4 mg/ml) (Figure 7B). In contrast, flavopiridol
did not markedly affect Akt1 activity (Figure 7B). As demonstrated
in Figure 7C, the inhibition of Akt1 with Akt-I-VIII induced a
dose-dependent apoptosis in U937 cells. Furthermore, combined
treatment with Akt-I-VIII and HF significantly increased the
percentage of apoptotic cells as compared to that of HF or Akt-I-
VIII alone (Figure 7C). These data strongly suggest that the pro-
apoptotic effect of HF is at least in part mediated by inhibition of
the Akt pathway, with suppression of Akt1 kinase activity and
downregulation of the phosphorylated form of Bad.
NF-kB pathway is not involved in HF-mediated cell
growth arrest and apoptosis
Studies have linked AML cell proliferation and survival to NF-
kB signaling pathway [30]. To assess whether NF-kB signaling
was involved in the inhibition of AML cell growth by HF, we used
stable transformant NB4 cells expressing a repressor form of Ik-
Ba,I k-Ba (A32/36) which acts like a constitutive repressor of NF-
kB activation [31]. The wild-type Ik-Ba was present in NB4/GFP
and NB4/GFP-MAD cells and, as expected, was degraded
following treatment with TNF-a (Figure 8A). A band correspond-
ing to mutated Ik-Ba was seen in the NB4/GFP-MAD cells only,
but was not affected by TNF-atreatment (Figure 8A). As reported
[31], the expression of Ik-Ba (A32/36) had no effect on the cell
viability and the proliferation rate of NB4-GFP-MAD cells
Figure 5. HF-induced apoptosis in U937 cells is caspase-dependent. (A) U937 cells were treated for 14 and 24 h with 1.4 mg/ml HF or left
untreated. Caspase-8, -9 and -3 activities were determined using IETD-pNA (caspase-8), LEHD-pNA (caspase-9) DEVD-pNA (caspase-3) respectively.
The release of pNA was measured at 405 nm. The data are expressed as fold-increase relative to respective untreated samples (basal values for
caspase-8, -9 and -3 activities were respectively 2360.02, 960.01 and 1360.02 pmol pNA/60 min/mg protein). Data are from three determinations 6
SD. (B) Lysates from U937, NB4 and OCI cells treated for 24 h with HF (1, 1.4, 2 mg/ml) were examined for PARP-1 expression by immunoblot. The
arrows indicate the cleaved form (cf) of PARP-1. (C) U937 cells were incubated with 1.4 mg/ml HF for 48 h after 1 h-pretreatment with 50 mM Z-VAD-
fmk (broad spectrum caspase inhibitor), Z-DEVD-fmk (caspase-3 inhibitor), Z-IETD-fmk (caspase-8 inhibitor) or Ac-LEHD-CHO (caspase-9 inhibitor). The
percentage of apoptotic cells was determined after annexin-V-FITC/PI staining and flow cytometry (L2+L4 gates). Data are the mean 6 SD of results
from 3 independent experiments. *P,0.05 compared with untreated cells or cells pretreated with caspase inhibitors.
doi:10.1371/journal.pone.0025963.g005
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presence of increasing concentrations of HF (0.5 and 1.4 mg/ml),
the growth of NB4-GFP-MAD cells for 72 h was inhibited to the
same rate than parental NB4 and NB4-GFP cells (Figure 8B). In
parallel, the levels of cell death were similar in parental, GFP and
GFP-MAD cells (Figure 8C). These data indicate that HF-
mediated apoptosis did not implicate the NF-kB pathway.
Discussion
HF exhibits anti-proliferative and pro-apoptotic activities
towards various cancers cells [4]. Akt1 signaling plays a major
role in AML survival and proliferation. The outcome of the
present study indicated that HF promoted apoptosis of established
AML cell lines defining distinct AML phenotypes and primary
AML cells cultured ex vivo. Our major findings showed that HF
blocked Akt1 activation by inhibiting its phosphorylation and
kinase activity; suppressed Bad phosphorylation which can activate
its pro-apoptotic function; activated the intrinsic pathway of cell
death by targeting mitochondria, anti-apoptotic Bcl-2, pro-
apoptotic Noxa, and caspases 29 and 23 in AML U937 cells.
Upon addition of HF in culture, the AML U937 cell line (FAB
M5/monoblast) underwent growth arrest followed by apoptosis, as
evidenced by accumulation of cells in the sub-G1 phase,
phosphatidylserine externalization and DNA fragmentation. HF
also exhibited antiproliferative and pro-apoptotic properties in
AML cell lines characterized by distinct FAB subtypes, HL-60
(M2/myeloblast), NB4 (M3/promyelocyte) and OCI (M4/myelo-
monocyte). All these cell lines have the abilities to differentiate into
monocytes/macrophages while NB4 and HL-60 cells can
differentiate into granulocytes. Analysis of morphologic and
phenotypic features specific to differentiating myeloid cells toward
granulocytes or monocytes/macrophages showed that differenti-
ation was not achieved in HF-treated cell lines (F Merhi,
unpublished results). This indicates that HF-induced cell death
was not a consequence of full terminal maturation. The results in
AML cell lines were confirmed in primary AML cells with HF-
mediated apoptosis observed in 14 of the 22 AML samples tested.
Unlike samples with FAB M0, M1, M2, M3, M5, the 2 AML
samples with FAB M4 did not respond to HF treatment. The
impact of HF on a larger number of AML samples from patients
with the M4 subtype needs to be investigated. Besides the direct
anti-tumor effect of HF on malignant cells, attention will have to
be laid on T cells and their antitumor responses from AML
samples, before and after in vitro HF treatment. Percentages of
residual T cells in AML samples will be evaluated and T cell
responses analyzed. Such a potential to activate antitumor directed
immune responses under HF treatment might be of benefit in
AML treatment.
Apoptosis can be initiated by the mitochondrial (intrinsic)
pathway and/or the death-receptor (extrinsic) pathway [20,32]. In
the intrinsic apoptosis pathway, proteins of Bcl-2 family, by
changing outer and inner membrane permeability of mitochon-
dria, regulate cytochrome C release from mitochondria, induce
caspase-9/-3 activation and PARP cleavage [20,32]. In the
extrinsic pathway, death receptor (such as Fas antigen and TNF-
R) triggering leads to strong caspase-8 activation, which bypasses
mitochondria, leading directly to activation of caspase-3 followed
by apoptosis [20,32]. We show that HF neither affected Fas levels
nor the amounts of secreted TNF-a (20–90 pg6ml
21/10
6 cells/
Figure 6. HF triggers a dissipation of the mitochondrial transmembrane potential associated with downregulation of Bcl-2 and Bid,
and upregulation of Noxa. (A&B) U937 cells were cultured for 24 h in the absence or presence of 1.4 mg/ml HF or 100 nM flavopiridol (F) (a
positive control of apoptosis in U937 cells). Then, cells were incubated for 15 min at 37uC with the fluorescent probe JC-1, subsequently washed and
distributed in triplicates in the wells of a microtitration plate. Green and red fluorescences were measured. The loss of mitochondrial membrane
potential is characterized by a a significant shift of the red (polarization) fluorescence to the green (depolarization) fluorescence. A) Representative
histograms showing flow cytometry analysis of polarization and depolarization. B) Quantification of the polarization to the depolarization ratio. Data
are expressed as mean 6 SD of three determinations. (C) U937 cells were treated with 1, 1.4 or 2 mg/ml HF or 100 nM F for 24 h, after which lysates
were subjected to Western blots using antibodies recognizing Bax, Bid, Bcl-2, Mcl-1, Noxa and actin. Two experiments representative of four are
shown.
doi:10.1371/journal.pone.0025963.g006
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that HF does not induce AML cell apoptosis through death
receptor triggering. However, small amounts of activated caspase-
8, like stress-induced signals inside the cell, can degrade Bid, a
member of Bcl-2 family, leading to a truncated Bid (tBid) that
stimulates efficient oligomerization of Bax and activates the
intrinsic pathway [24]. Bid can be cleaved not only by caspase-8
but also by other caspases, granzyme B, calpains and cathepsins
[33]. Full-length Bid can also translocate to and activate the
mitochondria without cleavage [24]. Here, we provide evidence
that HF induced mitochondrial membrane perturbation, caspase-
9/-8/-3 activation, and decreased Bid levels without the
appearance of tBid in U937 cells. The results of caspase inhibition
studies argue strongly that caspase-8, in contrast to caspase-9 and
caspase-3, did not play a primary role in the apoptotic response to
HF. Similarly, flavopiridol favors apoptosis in U937 cells through
the mitochondrial pathway and independently of activation of pro-
caspase-8 and Bid cleavage [34]. Together our data indicate that
HF triggers cell death by apoptosis at least through the intrinsic
pathway and is not dependent upon the extrinsic, procaspase-8-
associated cascade. In addition, Bid has been shown to upregulate
cell proliferation and to participate in cell cycle arrest arrest [24].
The downregulation of Bid protein by HF in U937 cells may
therefore represent a possible mechanism by which Bid could
modulate growth arrest.
Members of Bcl-2 family such as pro-apoptotic Bad, Bax, Noxa
and anti-apoptotic Bcl-2, Mcl-1 proteins are important regulators
of the intrinsic pathway [20]. Overexpression of Bcl-2 protein
rescues U937 cells from apoptosis [35]. While Ser
136-phosphor-
ylation of Bad protects AML cells from apoptosis [27],
dephosphorylated Bad favors apoptosis by sequestering Bcl-2 in
the cytoplasm, thus preventing its binding to Bax which promotes
cytochrome C release [36]. Mcl-1 also blocks cytochrome C
release from mitochondria by preventing Bax activation [36]. In
addition, Noxa plays an important role in cell death decision by
targeting Mcl-1 for proteasomal degradation [37]. Noxa up-
regulation is associated with apoptosis of LLC cells induced by HF
[15]. In the present study, HF induced Ser
136-dephosphorylation
of Bad, downregulated levels of Bcl-2 and increased levels of Noxa
in U937 cells. We propose that Bad and Noxa by neutralizing
respectively the anti-apoptotic proteins Bcl-2 and Mcl-1 could
contribute to the apoptotic effect of HF.
The cAMP-responsive element binding protein (CREB) acti-
vates the transcription of the Bcl-2 gene [38]. Phosphorylation of
CREB at Ser
133 by the serine/threonine kinase Akt1 is required
for CREB-mediated transcription [39]. In addition, the Bcl-2
mRNA contains multiple predicted miRNA binding sites impli-
cated in the inhibition of Bcl-2 expression [40]. With regard to
Noxa, several regulators and control mechanisms have been
described [37]. The transcription factors implicated in regulating
Noxa expression include p53, hypoxia-inducible factor Hif-1a and
E2F1 [37]. Upregulation of Noxa mRNA and protein is
independent of p53 in various cell types [37,41,42]. In T cells,
Noxa stimulation interferes with PKC signaling and the common
Figure 7. HF induces the dephosphorylation of Bad and Akt, and inhibits Akt1 kinase activity. (A) U937 cells were treated with 1, 1.4 or
2 mg/ml HF or 100 nM F for 24 h, after which lysates were subjected to Western blots using antibodies recognizing Ser
136-p-Bad, Bad, Ser
473-p-Akt1,
Akt1 and actin. One experiment representative of three is shown. (B) Akt1 kinase activity was determined using a kinase assay kit obtained from
Enzolifesciences France using recombinant active Akt1 in the absence or presence of increasing concentrations (0.5–5.5 mM) of Akt1/2 inhibitor Akt-I-
VIII, F (flavopiridol), HF or vehicles EtOH (for HF) and DMSO (for F and Akt-I-VIII). Of note, 2.5 mM of HF corresponds to 1.4 mg/ml. Percent of Akt kinase
activity was determined. (C) The percentage of apoptotic cells was determined after annexin-V-FITC/PI staining and cytometry, under control
conditions, or 1.4 mg/ml HF or Akt-I-VIII (2.5, 5 and 10 mM) and in combination treatment for 48 h. Data are the mean 6 SD of results from 2
independent experiments.
doi:10.1371/journal.pone.0025963.g007
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and Bcl-2 are regulated by HF at the transcriptional or post-
transcriptional levels remains to be determined.
The Akt1 pathway participates in the regulation of proliferation
and apoptosis [43]. Full activation of Akt1 is a multiprocess, and
the final step is to phosphorylate Akt1 on two sites, Thr
308 and
Ser
473 residues [40]. The kinases PDK2 and mTORC2 as well as
Akt1 itself phosphorylate Akt1 at Ser
473 [40]. Primary AML cells
and AML cell lines express Akt1 and mTORC2 [25,44,45].
Activated Akt signaling protects AML cells from apoptosis [25].
Bad is a direct downstream target of Akt1 and may reflect the state
of Akt signaling [25]. Akt1 negatively regulates apoptosis of AML
cells through phosphorylation of Bad on Ser
136 [27] while
dephosphorylated Bad favors apoptosis [36]. As mentioned above,
we found that HF downregulated the levels of Ser
136-phosphor-
ylated Bad in U937 cells. We thus evaluated whether HF
interfered with Akt1 activity. The potential effect of HF on Akt1
has not been reported so far. We present new evidence that HF
downregulates the level of the active form of Akt1 through its
dephosphorylation in U937 cells. We further confirmed that HF
directly inhibits Akt1 kinase activity in an ELISA assay using a
recombinant Akt1 protein. Akt1 comprises a N-terminal pleckstrin
homology (PH) domain, a flexible hinge between the PH and the
kinase domain, a catalytic (kinase) domain and a C-terminal
regulatory domain (containing a hydrophobic Ser
473phosphoryla-
tion motif)[46,47]. The PH domain, the hinge region and the C-
terminal HM of Akt1 appear important for the inhibitory function
of the specific allosteric inhibitor Akt1/2 inhibitor Akt-I-VIII
[46,48]. Further studies are required to identify the potential
interactions between HF and these domains. This study therefore
support a novel function of HF as a negative regulator of Akt1.
Furthermore, inhibition of the Akt pathway by Akt-I-VIII induced
apoptosis in U937 cells, and combined treatment with Akt-I-VIII
and HF significantly increased the levels of apoptosis in
comparison with treatment with HF alone. These observations
strongly suggest that HF-mediated apoptosis involves inhibition of
the Akt pathway. Of note, flavopiridol inhibits the levels of Ser
473-
phosphorylated Akt1 without marked inactivation of Akt1 kinase
activity. In accordance, flavopiridol was previously shown to
diminish phosphorylation of Akt in myeloid K562 and HL-60 cells
[28,29]. Initially described as a potent inhibitor of cyclin-
dependent kinases (CDKs) by binding to the ATP-binding domain
of CDKs, flavopiridol lacks absolute specificity, insofar it can
inhibit other kinases, including Akt, p38MAPK, JNK, PKC and
IkBa kinase [29,49,50]. mTOR inhibitors prevent CDK activa-
tion [51]. Thus, whether flavopiridol could inhibit mTORC2
implicated in Akt1 phosphorylation cannot be excluded. More-
over, the regulation of Akt depends on the balance between
phosphorylation by kinases for activation and dephosphorylation
by phosphatases for inactivation [52,53]. Primary AML cells
express various levels of protein Ser/Thr phosphatases (PP1,
PP2A, PP2B, PP2C) [54]. PP2A activation by PP2A activators
such as forskolin or FTY720 blocks proliferation, induces caspase-
dependent apoptosis and decreases phosphorylation of Akt in
AML cells [55]. Whether flavopiridol plays a role in the activation
of PPs will require further investigation.
Other phosphorylated downstream targets of Akt include p53
and IkB kinase [25]. The p53 tumor-suppressor has a central role
in responses to DNA damage and determination of whether cells
undergo cell cycle arrest or apoptosis [56]. NB4 and OCI cell lines
express p53 [57,58] while HL-60 and U937 cells are p53 null [59].
In this study, all the cell lines were equally sensitive to the
inhibitory activity of HF thus indicating that HF-mediated
apoptosis operates through a p53-independent mechanism in
AML cells. Akt1 can promote cell survival via activation of NF-kB,
by phosphorylating IkB kinase IKKa which in turn phosphory-
lates and triggers Ik-Ba degradation via the ubiquitin-proteasome
pathway. Liberated NF-kB dimer translocates to the nucleus and
activates numerous target genes involved in the control of cellular
responses including apoptosis [30,39]. Increased IkB kinase
activity is associated with activated NF-kB in AML blasts thus
favoring neoplastic cell survival [60]. Here, blocking NF-kB
activity in NB4 cells transfected with a dominant-negative mutant
form of Ik-Ba that cannot be phosphorylated and degraded, did
not prevent the inhibitory effect of HF on cell growth and survival.
These data indicate that the mechanism by which HF induces
apoptosis of AML cells does not involve the inhibition of NF-kB.
In conclusion, this study emphasizes the role of HF in the
induction of apoptosis in AML cells associated with inhibition of
Akt1 and activation of the mitochondrial caspase-dependent
cascade, and a model is proposed in Figure 9. Accordingly, recent
studies have documented the convergence of protein kinases and
caspases in the regulation of cell proliferation and survival [56].
Pharmacokinetics studies performed in humans have demon-
strated oral bioavailability of HF [61–63]. Outcomes for patients
with AML have not significantly improved in the past 20 years and
conventional cytarabine- and anthracycline-based chemotherapy
remains the gold standard. Despite the activity of these agents,
20% of patients #60 years and 50% of older patients fail to
achieve remission with these standard agents, and only a small
proportion patients have a prolonged disease-free survival [64].
Chemoresistance to standard agents appears to be related, in part,
to overexpression of the protein P-gp which is the product of the
MDR1 (or ABCB1) gene and the prototype of the family of ABC
Figure 8. HF-induced apoptosis is independent on NF-kB
activation. (A) NB4/GFP cells and NB4/GFP-MAD cells were left
untreated or were incubated for 15 min with TNF-a (20 ng/ml), after
which lysates were subjected to Western blots using antibodies
recognizing Ik-Ba and actin. (B) cell growth and (C) apoptosis of wild
NB4, NB4/GFP and NB4/GFP-MAD cells (10
5/ml) treated with HF at the
indicated concentrations for 72 h. Data are the mean 6 SD of results
from 4 independent experiments.
doi:10.1371/journal.pone.0025963.g008
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resistance (MDR). P-gp functions by pumping certain drugs out
cells, through an active energy-dependent mechanism [65,66].
Our laboratory previously showed that HF is capable of inhibiting
the functional activity of Pgp in leukemic cells [67]. Therefore, our
findings may provide a new experimental basis for AML therapy
that have to be confirmed with an in vivo leukemia models in mice.
Several mouse models of human AML have been generated using
transgenic, gene targeting and retroviral transduction/transplan-
tation approaches [68–70]. In the model system generated by
Kharas and colleagues using a myristoylated Akt1, recipients
develop myeloproliferative disease, T-cell lymphoma or AML
[69]. This model with enhanced Akt activation could be exploited
to study the impact of HF.
Finally, dysregulation of Akt is observed in many cancers and
other diseases such as diabetes, cardiovascular and neurological
diseases [47]. Akt is considered as an attractive therapeutic target
for cancer treatment, and novel Akt inhibitors are being developed
[71,72]. The discovery of HF as a novel Akt1 inhibitor may have
implications for disease biology and treatment.
Materials and Methods
Ethics statement
The study was conducted and monitored in compliance with the
Declaration of Helsinki 2002. Ethics approval was given by the
Institutional Review Board of Paris-Saint-Antoine Hospital and of
the French National Institute of Cancer (‘‘Tumorothe `que
He ´matologie’’ Paris-Saint-Antoine Hospital COHO0203 INCA
2007). Peripheral blood samples from patients were obtained after
written informed consent (formulary EORTC study Nu06012).
Control blood samples from healthy and fully anonymized donors
were purchased from the Etablissement Franc ¸ais du Sang (Paris-
Ho ˆtel-Dieu Hospital) and required no special written informed
consent.
Cells and treatments
Blood samples from healthy donors were obtained from the
Paris-Ho ˆtel-Dieu Hospital. Leukemic blood samples from 22
treatment-naive AML patients (12 men and 10 women; age range:
25–80) were obtained the ‘‘Tumorothe `que He ´matologie’’ Paris-
Saint-Antoine Hospital. Diagnosis was established according to
standard clinical criteria and the FAB committee’s cytological
criteria. Peripheral blood mononuclear cells (PBMCs) were
separated by Ficoll-Hypaque density gradient (1.077 g/ml)
centrifugation. Cells (10
6/ml) were cultured in complete RPMI
1640 medium supplemented with 10% FCS.
The mycoplasma-free AML cell line U937 (ATCC CRL-
1593.2; French-American-British/FAB phenotype M5 mono-
blast), OCI-AML3 (M4, myelomonocyte)[73], NB4 (M3, promy-
elocyte)[74] and HL-60 (ATCC 240-CCL; M2, myeloblast) were
cultured in RPMI 1640 medium (Gibco, Paisley, UK) supple-
mented with 5% heat-inactivated fetal calf serum (FCS, Gibco;
LPS levels ,0.1 ng/ml), 2 mM L-glutamine, 1 mM sodium
Figure 9. Putative model for the convergent roles of Akt1 and mitochondrial caspase-dependent signaling pathways in the
induction of apoptosis by HF in AML cells. HF inactivates Akt1 leading to dephosphorylation of proapoptotic Bad, and downregulates anti-
apoptotic Bcl-2 protein. Dephosphorylated Bad sequesters Bcl-2 in the cytoplasm, favoring Bax translocation to the mitochondria. HF induces
upregulation of Noxa which exerts its pro-apoptotic function by neutralizing the prosurvival Mcl-1, facilitating activation of Bax. Subsequent
oligomerization of Bax inserts into the outer mitochondrial membrane, and triggers cytochrome c release. Cytochrome c forms a complex with
procaspase-9, Apaf-1 and dATP (apoptosome). The apoptosome activates caspase-9 which then activates caspase-3 ultimating leading to apoptosis.
doi:10.1371/journal.pone.0025963.g009
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humidified atmosphere at 37uC. NB4 cells transfected with the
Migr-eGFP vector (NB4/GFP cells) or with the Ik-Ba (A32/36)-
encoding Migr-eGFP (NB4/GFP-MAD) were generated as
previously described [31]. Cells were used at passage 12 or less
and harvested in log-phase growth for every experiment. Cells (1-
3610
5/ml) were treated with various concentrations (0.1–3 mg/
ml) of HF for various periods of time. Flavopirirol (100 nM) was
used as a positive control for apoptosis induction. In negative
control experiments, cells were treated with the same volume of
EtOH (vehicle) used to dissolve HF. Caspase inhibitors were
added at the beginning of the cultures and incubated for 60 min
prior to the addition of HF.
Reagents
HF (Figure 1) was purified according to the method described
[75]. Stock solutions (1 mg/ml) were made in ethanol (EtOH).
Flavopiridol (10 mM stock solution prepared in DMSO) was gifted
by Aventis Pharmaceuticals (Bridgewater, NJ, USA). Fluorescein
isothiocyanate (FITC)-conjugated anti-CD15 (80H5, mIgM),
FITC-anti-CD11b (BEAR 1, mIgG1), FITC-CD44 (mIgG1, J-
173), phycoerythrin (PE)-conjugated anti-CD13 (mIgG1, SJ1D1)
and FITC-mIgM were obtained from Beckman-Coulter (Luminy,
France). FITC-mIgG1, PE-mIgG1, anti-phospho-Ser
136-Bad
(Ser
136, rabbit IgG), anti-PARP-1 (F-2, mIgG2a) and anti-Bad
(H-168, rabbit IgG) were from Santa-Cruz (Tebu-Bio SA, Le
Perray en Yvelines, France). Z-IETD-fmk (a caspase-8 inhibitor)
and caspase-3/-8/-9 kit assays were obtained from R&D
(Abingdon, UK). Anti-phospho-Ser
473-Akt1 (193H12, rabbit
IgG), anti-Akt1 (H-136, rabbit IgG), anti-Bid (FL-195, rabbit
IgG), anti-Bcl2 (100, mIgG1) and anti-Mcl-1 (S-19, rabbit IgG)
were from Cell Signaling (Hertfordshire, UK). Anti-actin (C4,
mIgG1) was from ICN Biomedicals (Ohio, USA). Anti-Bax
(mIgG1) was from Zymed Laboratories (San Francisco, USA).
Anti-Noxa (6D619, mIgG1) was from US Biologicals/Euromedex
(Mundolsheim, France) Secondary antibodies were horseradish
peroxidase-conjugated from GE Healthcare Life Sciences (Picat-
away, NJ, USA). Z-DEVD-fmk (a caspase-3 inhibitor), Z-VAD-
fmk (a general caspase inhibitor) and Akt inhibitor VIII (an Akt1/
Akt2 inhibitor) were from Calbiochem (Darmsdat, Germany). Ac-
LEHD-CHO (a caspase-9 inhibitor) was from AG Scientific, Inc.
(San Diego, CA, USA). Active human recombinant Akt1 was
supplied by Cell Sciences (Canton, MA).
Determination of cell growth, cell death and cell cycle
Cell growth was evaluated by counting the number of viable
cells (with diameters ranging from 9 to 14 mm) and dead cells
(diameters ranging from 4 to 9 mm) in a Coulter Multisizer
(Beckman-Coulter, Les Ullis, France). Cell cycle status was
determined as described in [76] and measured with a flow
cytometer (Beckman-Coulter, Luminy, France). The amount of
cells in sub-G1, G0/G1, S and G2/M phases was calculated using
the Win cycle software (Beckman-Coulter).
Flow cytometry
Apoptosis was measured using the annexin-V-FITC/propidium
iodide (PI) apoptosis detection kit (Beckman-Coulter). Stained cells
(40,000) (AML cell lines and primary blasts) were analyzed using
the flow cytometer (Beckman-Coulter). Induction of maturation
was assayed by immunostaining intact HL-60, NB4 and U937cells
with mAbs directed against CD11b (macrophagic marker)[77],
CD13 (macrophagic marker), CD15 (granulocytic marker) and
CD44 (macrophagic marker)[74,78]. Cells to be stained (2610
5)
were centrifuged to form a pellet and incubated with the
appropriate mAbs or isotypes under saturating concentrations
(1 mg) for 30 min on ice, then washed twice with PBS
supplemented with 1% bovine serum albumin and 0.1% sodium
azide, and fixed with 0.4% formaldehyde in PBS. Cell fluorescent
intensity (40,000 cells) was measured using the flow cytometer
(Beckman-Coulter). Values were given as percentages of positive
cells [79].
DNA fragmentation
Cells were washed twice with PBS and lysed in M-PER buffer
(ThermoFisher Scientific, Ilkirch, France) for 60 min on ice.
Lysates containing fragmented DNA were cleared by centrifuga-
tion at 10,000 g for 15 min. Supernatant samples were treated
with proteinase K (500 mg/ml) at 50uC for 2 h. Thereafter,
RNAse A (500 mg/ml) was added and the samples were incubated
at 50uC for 90 min. Electrophoresis was performed in 1.8%
agarose gels containing ethidium bromide and the bands were
analyzed in an Appligen Oncor densitometer (Illkirch, France).
Assessment of mitochondrial membrane permeability
The loss of mitochondrial membrane potential (MMP) was
analyzed using the mitochondrial detection kit (Biomol GmbH,
Hamburg, Germany) as described previously [14]. Following drug
treatment, cells were labeled with the lipophilic fluorochrome dye
JC-1. The sample’s fluorescence was recorded in a Wallac Victor 2
multitask plate reader (Perkin Elmer, Norwalk, MT, USA). The
depolarization of MMP is characterized by a shift from red
fluorescence (FL2) to green fluorescence (FL1), i.e. a reduction in
the red/green fluorescence ratio. The simultaneous detection of
FL1 and FL2 was also performed by flow cytometry.
Caspase assays
Caspase-3, -8 and -9 activities were assayed with specific
substrates for caspase-3 (DEVD-pNA), caspase-8 (IETD-pNA) and
caspase-9 (LEHD-pNA) in cell lysates (100 mg/assay) using the
caspase cellular activity assay kits (R&D Systems) according to the
manufacturer’s instructions. Formation of pNA was monitored at
405 nm. Comparison of the absorbance of pNA from a treated
sample with control sample allows determination of the relative
increase in caspase activity.
Western blot analysis
Cells were lysed in M-PER buffer (Pierce Biotechnology,
Rockford, IL, USA) supplemented with protease and phosphatase
inhibitor cocktails (Sigma). Total cell extracts were separated on
12% SDS-PAGE, transferred to nitrocellulose and blotted as
described previously [80]. Immunoblotting was performed with
primary antibodies diluted according to the manufacturer’s
instructions and samples were then incubated with HRP-coupled
secondary antibodies. Blots were visualized by enhanced chemi-
luminescence (ECL, GE Healthcare Europe, Saclay, France) and
NIH Image 1.63 software was used to quantify the intensity of the
bands.
Akt1 kinase activity assay
Akt1 kinase activity assay was carried out using the commercial
kit (EKS-400A) from Enzolifesciences France (Villeurbanne,
France) following the manufacturer’s protocol. The assay is based
on a solid phase ELISA that utilizes a specific synthetic peptide as
a substrate for active human recombinant Akt1 and a polyclonal
antibody that recognizes the phosphorylated form of the substrate.
Controls included vehicles EtOH (for HF) and DMSO (for Akt 1/
2 inhibitor/Akt-I-VIII).
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Data are presented as means 6 SD from n independent
experiments. Results are expressed as the mean 6 SD. A two-
tailed, paired Student’s t-test was used to compare test and control
groups. The threshold for statistical significance was set to P,0.05.
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